Recent Updates
Recently added Catalysts
BAX Positive Sentiment

Baxter Reports Third-Quarter 2026 Results

Thursday, October 29, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Baxter International Inc. reported strong third-quarter results for 2026, highlighting growth across all segments. CEO Andrew Hider noted steady progress in stabilizing the business and improving the balance sheet. The results reflect confidence in the company's direction and efforts to build a stronger foundation.

Market Sentiment Analysis

POSITIVE FACTORS

  • Growth reported across all global segments
  • CEO cites steady business stabilization progress
  • Balance sheet strengthening noted by management
  • Company reports continuous operational improvement

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+71%
120-day peak, hindsight
Typical move
2.1%
average across 13 past catalysts
Lead asset
Glycerophosphate
Phase 1 · Parenteral Nutrition

Full Press Release Details

DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a global medtech leader, today reported results for the third quarter of 2026. “We delivered a strong third quarter, with growth across all segments and divisions globally,” said Andrew Hider, president and CEO. “We continue to make steady progress stabilizing the business, strengthening the balance sheet and driving continuous improvement. Our results reinforce our confidence in this direction as we build a stronger founda

Frequently Asked Questions

What were Baxter's results for Q3 2026?

Baxter reported strong growth across all segments in Q3 2026.

Who is the CEO of Baxter?

Andrew Hider is the president and CEO of Baxter International.

What improvements did Baxter mention?

Baxter highlighted progress in stabilizing the business and strengthening its balance sheet.

What is Baxter's outlook based on Q3 results?

The results reinforce Baxter's confidence in their strategic direction.

ShareAdd on Google
Tags: BAX Baxter International Q3 2026 financial results medtech
Last updated: Oct 29, 2026

Biotech snapshot

Cash runway
$2150M liquidity · $0M/mo burn
Low dilution risk
Lead asset
GlycerophosphatePhase 1
Parenteral Nutrition →

Catalyst track record

+71%
best trade around BAX's most recent catalyst

Peak hindsight return over a 120-day window, across 13 tracked FDA/PDUFA catalysts for BAX.

See every catalyst's timing & PoA →